Blog
A solution for improving recruitment into early Alzheimer’s disease clinical trials
Screening patients into early stage Alzheimer’s trials can be costly and time-consuming. Kenton Zavitz, PhD, Director of Clinical Affairs proposes a potential solution for improving recruitment into clinical trials.
The challenge of detecting early Alzheimer’s disease for clinical trials
In this post, Director of Clinical Affairs, Dr Kenton Zavitz, looks at the challenge of recruiting the correct patients into Alzheimer's disease trials.
What does the new FDA guidance mean for clinical trials in early Alzheimer’s disease?
The latest FDA draft guidance for clinical trials in early Alzheimer’s disease presents many new opportunities and challenges for drug development.
WEBINAR: Finding the right patients for clinical trials in early Alzheimer's disease
Dr Kenton Zavitz, Director of Clinical Affairs at Cambridge Cognition, and Dr Robert Smith, Consultant Neuropsychologist, hosted a webinar to discuss clinical trials for early Alzheimer’s disease.
Join them to hear more about overcoming the barriers to expedite the drug development process.
Tuesday 22nd May 2018, 11 a.m. EDT
Speech recognition and online assessments: the future for clinical trials in Alzheimer's disease?
New data demonstrates possibility for speech recognition and online assessments to enhance clinical trials in Alzheimer’s disease.
The CANTAB Paired Associates Learning task as a pre-screening tool for clinical trials
Enriching participant eligibility for clinical trials through pre-screening for cognitive deficit.
